目的:对桑叶中1-脱氧野尻霉素的提取条件进行优化后研究其对高糖诱导的肾小球系膜细胞凋亡和炎性因子的影响。方法:建立1-脱氧野尻霉素的定量检测方法,探讨桑叶中1-脱氧野尻霉素的最佳提取条件。培养小鼠肾小球系膜(SV40 MES 13)细胞,...目的:对桑叶中1-脱氧野尻霉素的提取条件进行优化后研究其对高糖诱导的肾小球系膜细胞凋亡和炎性因子的影响。方法:建立1-脱氧野尻霉素的定量检测方法,探讨桑叶中1-脱氧野尻霉素的最佳提取条件。培养小鼠肾小球系膜(SV40 MES 13)细胞,并分为四组:正常对照组(PBS)、高糖组(30 mmoL/L葡萄糖)和1-脱氧野尻霉素组(2、50μM),给药结束后采用CCK-8法测定SV40 MES 13细胞的存活率,ELISA测定炎性因子单核细胞趋化蛋白1(Monocyte chemoattractant protein-1,MCP-1)、肿瘤坏死因子α(Tumor necrosis factor-alpha,TNF-α)和白细胞介素6(Interleukin-6,IL-6)的水平。最后用Western blotting法检测细胞增殖蛋白Cyclin D1和PCNA的表达水平。结果:桑叶中1-脱氧野尻霉素的提取条件最终优化为料液比1∶15 g/mL、pH值3.0和提取时间30 min。1-脱氧野尻霉素明显提高SV40 MES 13细胞的存活率,并下调炎性因子IL-6的表达水平,且高剂量的1-脱氧野尻霉素显著降低Cyclin D1和PCNA的表达。结论:选择合适的料液比、pH值和提取时间可优化桑叶中1-脱氧野尻霉素的提取工艺,此外,1-脱氧野尻霉素具有改善高糖诱导的肾小球系膜细胞凋亡的作用,其作用机制与调控炎性因子及相关增值蛋白的表达有关。展开更多
Glucagon-like peptide-1 receptor （GLP-1R） agonists are widely used for treating type 2 diabetes mellitus （T2DM） be- cause of their glucose-lowering and weight-losing effects, and low risk of hypoglycemia. Hence, t...Glucagon-like peptide-1 receptor （GLP-1R） agonists are widely used for treating type 2 diabetes mellitus （T2DM） be- cause of their glucose-lowering and weight-losing effects, and low risk of hypoglycemia. Hence, there is considerable interest in understanding the mechanism underlying the beneficial effects of GLP-I and developing stable and effective GLP-1R agonists. Here, we summarize the presently known mechanism of GLP-I actions, which are mainly through regulating cAMP-PKA signaling pathway; the latest developments in novel clinical GLP-1R agonists are also introduced, which are characterized with multiple properties, such as extended half-life, reduced side-effects, lower production costs and more convenient drug dosing mode. The potential risk of GLP-I-based therapeutics, an often-ignored fact, is also discussed.展开更多
基金Supported by the Natural Science Foundation of China(81172971,81222043)the Program for New Century Excellent Talents in University(NECT11-0170)+2 种基金the Municiple Key Technology Program of Wuhan(Wuhan Bureau of Science & Technology,201260523174)the Clinical Research Foundation of the Health Bureau of Wuhan(WX12B06)the Natural Science Foundation of Hubei Province(2013CFB359)
文摘Glucagon-like peptide-1 receptor （GLP-1R） agonists are widely used for treating type 2 diabetes mellitus （T2DM） be- cause of their glucose-lowering and weight-losing effects, and low risk of hypoglycemia. Hence, there is considerable interest in understanding the mechanism underlying the beneficial effects of GLP-I and developing stable and effective GLP-1R agonists. Here, we summarize the presently known mechanism of GLP-I actions, which are mainly through regulating cAMP-PKA signaling pathway; the latest developments in novel clinical GLP-1R agonists are also introduced, which are characterized with multiple properties, such as extended half-life, reduced side-effects, lower production costs and more convenient drug dosing mode. The potential risk of GLP-I-based therapeutics, an often-ignored fact, is also discussed.
